
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 17)*

Pulse Biosciences, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

(CUSIP Number)

ADAM W. FINERMAN, ESQ.
BAKER HOSTETLER LLP, 45 Rockefeller Plaza
New York, NY, 10111
(212) 589-4233

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

05/11/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

Name of reporting person

1

ROBERT W. DUGGAN

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3 SEC use only
Source of funds (See Instructions)

4 PF
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 UNITED STATES

Sole Voting Power

7

49,706,423.00

Number of Shares Beneficially

Shared Voting Power

Owned by

8

0.00

Each Reporting Person

Sole Dispositive Power

9

49,706,423.00

With: Shared Dispositive Power

10

0.00

Aggregate amount beneficially owned by each reporting person

11 49,706,423.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12
Percent of class represented by amount in Row (11)

13 71.9 %

Type of Reporting Person (See Instructions)

14 IN

Comment for Type of Reporting Person: *Represents 49,706,423 shares of Common Stock, including (i) 256,078 shares of Common Stock underlying certain options exercisable within 60 days hereof, held by Mr. Duggan, (ii) 630,109 shares of Common Stock held by Genius 24C Inc d/b/a Genius Inc and (iii) 450,189 shares of Common Stock held by Blazon Corporation. This does not include options which are not exercisable in 60 days from the date hereof. The number of shares of Common Stock beneficially owned by Mr. Duggan reported in the table above does not include shares of Common Stock which are beneficially owned by Mr. Duggan's spouse, Dr. Maky Zanganeh. As spouses, Mr. Duggan and Dr. Zanganeh may be deemed to have acquired beneficial ownership of the securities held by the other spouse upon their marriage on December 18, 2024. Mr. Duggan does not hold any voting or investment power over such securities held by Dr. Zanganeh. Mr. Duggan disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Percent beneficially owned is based on 69,141,378 shares of Common Stock outstanding, consisting of (i) 68,225,067 shares outstanding as disclosed in the Issuer's Proxy Statement filed with the Securities and Exchange Commission on May 11, 2026, (ii) 256,078 shares underlying options that can be exercised by Mr. Duggan within 60 days hereof and (iii) 660,233 shares of Common Stock issued by the Issuer through its at-the-market equity offering program.

SCCHEDULE 13D

CUSIP No.

Name of reporting person

1 GENIUS 24C INC

2 Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 FLORIDA
Sole Voting Power

7 630,109.00
Number of Shares Beneficially Owned by Each Reporting Person With:

8 0.00
Shared Voting Power
Sole Dispositive Power

9 630,109.00
Shared Dispositive Power

10 0.00
Aggregate amount beneficially owned by each reporting person

11 630,109.00
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12
Percent of class represented by amount in Row (11)

13 0.9 %
Type of Reporting Person (See Instructions)

14 CO

Comment for Type of Reporting Person: * Represents 630,109 shares of Common Stock held by Genius 24C Inc d/b/a Genius Inc. Percent beneficially owned is based on 68,885,300 shares of Common Stock outstanding, consisting of (i) 68,225,067 shares outstanding as disclosed in the Issuer's Proxy Statement filed with the Securities and Exchange Commission on May 11, 2026, and (ii) 660,233 shares of Common Stock issued by the Issuer through its at-the-market equity offering program.

SCHEDULE 13D

CUSIP No.

1 Name of reporting person
BLAZON CORPORATION
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

| | | |
|--|--------------------------|--|
| | <input type="checkbox"/> | Citizenship or place of organization |
| 6 | | CALIFORNIA |
| | | Sole Voting Power |
| | 7 | |
| Number of Shares Beneficially Owned by Each Reporting Person | | 450,189.00 |
| | | Shared Voting Power |
| | 8 | |
| | | 0.00 |
| | | Sole Dispositive Power |
| | 9 | |
| | | 450,189.00 |
| With: | | Shared Dispositive Power |
| | 10 | |
| | | 0.00 |
| | | Aggregate amount beneficially owned by each reporting person |
| 11 | | 450,189.00 |
| | | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) |
| 12 | | |
| | <input type="checkbox"/> | Percent of class represented by amount in Row (11) |
| 13 | | 0.7 % |
| | | Type of Reporting Person (See Instructions) |
| 14 | | CO |

Comment for Type of Reporting Person: * Represents 450,189 shares of Common Stock held by Blazon Corporation. Percent beneficially owned is based on 68,885,300 shares of Common Stock outstanding, consisting of (i) 68,225,067 shares outstanding as disclosed in the Issuer's Proxy Statement filed with the Securities and Exchange Commission on May 11, 2026, and (ii) 660,233 shares of Common Stock issued by the Issuer through its at-the-market equity offering program.

SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

(a)

Common Stock, par value \$0.001 per share

Name of Issuer:

(b)

Pulse Biosciences, Inc.

Address of Issuer's Principal Executive Offices:

(c)

601 Brickell Key Drive, Suite 1080, Miami, FLORIDA , 33131.

Item 1 Comment: The following constitutes Amendment No. 17 to the Schedule 13D filed by the undersigned. This Amendment No. 17 amends the Schedule 13D as specifically set forth herein.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 is hereby amended and restated to read as follows: The aggregate purchase cost of the 49,706,423 shares of common stock beneficially owned by Mr. Duggan is approximately \$414,666,603 including brokerage commissions. Such shares were acquired with personal funds (with the exception of the 630,109 shares owned Genius 24C Inc d/b/a Genius Inc and the 450,189 shares owned by Blazon Corporation. Mr. Duggan received his 256,078 stock options in connection with his service on the board of directors of the Issuer). The aggregate purchase cost of the 630,109 shares of Common Stock owned by Genius 24C Inc d/b/a Genius Inc ("Genius"), which Mr. Duggan is the sole shareholder of and may be deemed to be beneficially owned by Mr. Duggan, is approximately \$5,957,491.56 including brokerage commissions. Such shares were acquired with working capital. The aggregate purchase cost of the 450,189 shares of Common Stock owned by Blazon Corporation ("Blazon"), which Mr. Duggan is the majority shareholder of and may be deemed to be beneficially owned by Mr. Duggan, is approximately \$4,284,178.60 including brokerage commissions. Such shares were acquired with working capital.

Item 5. Interest in Securities of the Issuer

(a) Items 5(a)-(c) are hereby amended to read as follows: The aggregate percentage of shares of Common Stock reported owned by each person named herein is based upon 68,885,300 shares outstanding consisting of (i) 68,225,067 shares outstanding as disclosed in the Issuer's Proxy Statement filed with the Securities and Exchange Commission on May 11, 2026, and (ii) 660,233 shares of Common Stock issued by the Issuer through its at-the-market equity offering program, and in the case of Mr. Duggan, an additional 256,078 shares underlying options that can be exercised by Mr. Duggan within 60 days hereof. A. Mr. Duggan As of the close of business on May 11, 2026, Mr. Duggan beneficially owned 49,706,423 shares of Common Stock, including 256,078 shares underlying certain options exercisable within sixty days hereof. As the sole shareholder of Genius, Mr. Duggan may be deemed the beneficial owner of the 630,109 shares of Common Stock held by Genius. As the majority shareholder of Blazon Corporation, Mr. Duggan may be deemed the beneficial owner of the 450,189 shares of Common Stock held by Blazon. Percentage: Approximately 71.9% B. Genius 24C Inc d/b/a Genius Inc As of the close of business on May 11, 2026, Genius beneficially owned 630,109 shares of Common Stock. Percentage: Approximately 0.9% C. Blazon Corporation As of the close of business on May 11, 2026, Blazon Corporation beneficially owned 450,189 shares of Common Stock. Percentage: Approximately 0.7%

Item 5(b) is hereby amended to read as follows: A. Mr. Duggan: 1. Sole power to vote or direct vote: 49,706,423 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 49,706,423 4. Shared power to dispose or direct the disposition: 0 B. Genius 24C In d/b/a Genius Inc.: 1. Sole power to vote or direct vote: 630,109 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 630,109 4. Shared power to dispose or direct the disposition: 0 C. Blazon Corporation: 1. Sole power to vote or direct vote: 450,189 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 450,189 4. Shared power to dispose or direct the disposition: 0

(b) Item 5(c) is hereby amended to read as follows: The transactions in the shares of Common Stock by the Reporting Persons during the past sixty days are set forth below in the table entitled "Transactions in the Common Stock During the Past Sixty Days." Transactions in the Common Stock During the Past Sixty Days Reporting Person Type of Security Securities Purchased / (Sold) Price Per Share(\$)
(c) Date of Purchase / Sale Mr. Duggan Common Stock
660,233 19.69(1) 5/11/2026 (1) The shares reported herein were acquired through the Company's at-the-market equity offering program established pursuant to that certain Equity Distribution Agreement, dated February 19, 2026, by and between the Company and TD Securities (USA) LLC, as sales agent. The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws. The shares reported herein were purchased at the prevailing market bid price or higher at the time of sale.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ROBERT W. DUGGAN

Signature: /s/ Robert W. Duggan

Name/Title: Robert W. Duggan

Date: 05/13/2026

GENIUS 24C INC

Signature: /s/ Robert W. Duggan

Name/Title: Robert W. Duggan, Authorized Signatory

Date: 05/13/2026

BLAZON CORPORATION

Signature: /s/ Robert W. Duggan

Name/Title: Robert W. Duggan, Authorized Signatory

Date: 05/13/2026